The global pharmacovigilance (PV) or drug safety market is projected to grow from $8.6bn in 2024 to $22.4bn by 2032.
Fundamental drivers shaping this growth include:
- Growing levels of drug consumption with increasing complexity of drugs being developed
- Increasingly stringent regulatory mandates and complex compliance requirements
- Technological advancements driving efficiencies in the PV market
- Continued trend of outsourcing in the pharma services industry, including of PV services
Anticipating an exciting growth outlook, the demand for pharmacovigilance (PV) is poised to fuel increased M&A activity.
To learn more about the key M&A trends taking shape this year in the pharmacovigilance space, read our latest paper.
DOWNLOAD THE FULL PAPER
If you would like to know more about the PV M&A landscape after reading this paper, or have any other questions on the wider pharmaceutical outsourcing space, please do get in touch - asultan@alvarezandmarsal.com.We would be delighted to discuss this report with you, including any implications these current and longer-term market themes may have on your business and overall shareholder objectives.
Alvarez & Marsal launches Public Company Advisory team and hires Corporate Finance Senior Director
December 1, 2025
London, 1 December 2025 – Leading global professional services firm Alvarez & Marsal (A&M) has bolstered its Corporate Finance practice with the launch of a new Public Company Advisory group and the appointment of Jamie Peel as a Senior Director in Manchester.
Neurodivergent Services M&A Market
September 29, 2025
Neurodiversity encompasses a spectrum of neurological conditions. With an estimated 1 in 7 people in the UK considered neurodivergent, demand for services is rising.
Alvarez & Marsal continues expansion of European Corporate Finance practice with senior strategic hires in Italy and France
September 22, 2025
A&M appoints Managing Directors Barbara MG Ronconi and Frédéric Meyer in Italy and France, respectively.
European Sporting Goods M&A Market
July 17, 2025
The European sporting goods industry, valued at €80 billion, is experiencing steady growth, with a projected CAGR of 4-6% to 2029. The sector further plays an important role in facilitating health and wellness by encouraging active lifestyles and supporting public health goals.
